Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCQB:XSNX - Post by User

Novaccess Global Inc > Going to .05c to.50c

<< Previous

Bullboard Posts

Next >>

Comment by Sonali1997on Jun 08, 2018 12:53pm

85 Views

Post# 28146650

RE:RE:RE:RE:Going to .05c to.50c

1:20. OR. 1:50 is too much for the roll back....more like 1:2. OR. 1:5. From 1.4B sgares 1:2 ==== 700M. ....... or. ..........1:5 ======= 280M. .............but 1:20 and 1:50 is like 70M to 28M......

teheran10 wrote: I believe in the next year or two we have to experience some rollback, for example 1:20 or 1:50. Nevertheless this company is just starting to surface. Even with the split we are looking at a few pennies, far cry from $1. This company can make you super rich boys and girls.

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price